Pharmaceutical & Biotech

Shadow AI in Pharma: Clinical Data at Risk

Researchers paste trial endpoints into AI summarisers. Regulatory affairs drafts FDA submissions with AI assistants. Medical science liaisons feed adverse-event data to chatbots. Your validated systems log none of it. A DNS log audit does.

Start Free Audit Sample Report

Why Pharma Shadow AI Threatens Drug Development

Pharmaceutical data carries unique sensitivity: clinical trial results, molecular structures, patient safety data and regulatory submissions. Every unsanctioned AI tool that touches this data creates FDA compliance risk and potential IP loss worth billions.

R&D and Discovery

Scientists paste molecular structures, compound libraries and assay results into AI tools. Proprietary drug candidates and screening data reach commercial AI platforms outside your IP firewall.

Clinical Trials

CRAs use AI to draft protocols, summarise endpoint data and generate safety narratives. Patient-level trial data, adverse events and efficacy signals flow to unvalidated AI systems.

Regulatory Affairs

RA teams use AI to draft CTD modules, IND amendments and FDA responses. Pre-submission data, regulatory strategy and agency correspondence reach external AI servers.

Manufacturing (GMP)

QA teams upload batch records, deviation reports and CAPA documentation to AI for analysis. GMP-critical process parameters and quality data bypass validated systems.

Pharmacovigilance

PV teams use AI to triage adverse-event reports and draft MedWatch submissions. Patient safety data and signal-detection outputs reach unvetted AI tools.

Medical Affairs

MSLs and medical writers use AI for literature reviews, slide decks and KOL briefings. Unpublished efficacy data and competitive intelligence leak through AI chat sessions.

Regulatory and Compliance Mapping

Requirement	Source	Shadow AI Risk	What the Audit Produces
Electronic Records	21 CFR Part 11	AI-generated content not in validated systems	AI tool inventory mapped to GxP process areas
Data Integrity	FDA / ALCOA+	AI outputs not attributable, legible, contemporaneous	Unvalidated AI tools flagged for data-integrity risk
Clinical Data Protection	ICH E6(R2) / GCP	Patient data in AI tools violates GCP and consent	AI services handling clinical data identified
Trade Secret Protection	DTSA / Patent law	Compound data in AI may trigger prior-art or IP loss	AI tools flagged by data sensitivity and training policy
Pharmacovigilance	21 CFR 314.80	AE data in unvalidated AI tools	PV-related AI tool usage with risk classification
Computer System Validation	GAMP 5 / Annex 11	AI tools used without validation or qualification	Complete AI tool list for CSV risk assessment

What Your Pharma Audit Report Shows

Sample excerpt from a shadow AI audit of a mid-size biotech company (600 employees, Phase II/III pipeline).

SHADOW AI AUDIT - BIOTECH COMPANY

Scan Period14 days (DNS + proxy)

Total AI Tools Found26 unique AI services

Tools on Validated List2 of 26

Tools Training on Input11 of 26

TOP FINDINGS

ChatGPT (Free Tier)1,624 queries - R&D and regulatory affairs

AI Writing Assistant743 sessions - medical writing team

AI Data Analysis298 uploads - clinical data extracts

AI Literature Search412 queries - medical affairs (low risk)

RISK BY DEPARTMENT

R&D / Discovery (IP and compound data)

Regulatory Affairs (submission data)

Clinical Operations (trial data)

Quality / Manufacturing

Related Resources

Industry

Healthcare

HIPAA and clinical AI risk in health systems.

Role Guide

For Compliance Officers

Multi-framework compliance evidence.

Compliance

GDPR and Shadow AI

For pharma companies processing EU patient data.

Compliance

HIPAA and Shadow AI

PHI protection in clinical research settings.

Pharmaceutical Shadow AI FAQ

Does the audit access clinical trial data?

No. The audit analyses DNS and proxy log files only. These contain domain names and timestamps. No patient data, trial results, compound information or regulatory documents are accessed.

How does this relate to 21 CFR Part 11?

Part 11 requires electronic records used in FDA-regulated processes to be created in validated systems with audit trails, access controls and electronic signatures. AI tools used outside your validated environment do not meet these requirements. The audit identifies which AI tools are being used in GxP contexts so you can bring them into your validation programme or block them.

Can this detect AI tools used by CRO partners?

If CRO staff connect through your network or VPN, their AI tool usage appears in your DNS logs. For CROs on their own networks, you can require log exports as part of your vendor oversight programme and run the same audit on their logs.

What about AI features in our LIMS or CTMS?

AI features embedded in laboratory information management systems or clinical trial management systems generate DNS traffic to their AI service endpoints. The audit identifies these, letting you verify they are covered by your vendor validation and that data handling meets GxP requirements.